



GSK SIGNS LICENSE TO MARKET BILASTINE IN SPAIN AND POLAND

GlaxoSmithKline has signed a license agreement with Menarini for the antihistamine bilastine. The license is for promotion and distribution in Spain and Poland of the product which was researched and developed by the Spanish company Faes Farma.

Bilastine is now approved in ten European countries, including Spain. Menarini holds the license the compound for 51 countries in the EU and CIS.

This agreement follows those in Greece with Vianex in 2009 and France and Belgium with Pierre Fabre in 2010.